218 results about "Thrombosis" patented technology

The invention discloses a deep venous thrombosis early warning method and system based on multi-modal physiological signals, and relates to the technical field of health monitoring. The method is used for realizing thrombus early recognition and graded early warning. The method comprises the following steps: synchronously acquiring physiological signals of lower limbs on two sides through a multi-modal sensing device, performing motion artifact elimination and signal quality screening, and generating preprocessed time sequence data; performing dynamic time warping and feature extraction on the time series data, calculating a bilateral symmetry index and an instantaneous and accumulated time-varying difference degree, and fusing the bilateral symmetry index and the instantaneous and accumulated time-varying difference degree with absolute physiological parameters to form a comprehensive risk assessment vector; establishing a dynamic baseline based on the historical risk vector, calculating a current deviation index, and recognizing an abnormal state in combination with a double-side cooperation mode; and according to the deviation index and the duration, in combination with the abnormality type and the severity, generating a graded early warning signal containing a risk grade and a disposal suggestion through multi-stage judgment, thereby realizing early warning and risk management of thrombus.

A prosthetic heart valve for the treatment of structural heart disease wherein the prosthetic heart valve includes an expandable frame that a) has an open cell geometry in the frame of the prosthetic heart valve that can be used to reduce delivery system size, b) has high radial strength, c) has improved restoration of the physiologic EOA, d) has lower recoil, e) has little or no longitudinal foreshortening, f) allows for proper placement of the bioprosthetic valve in relation to the native commissures of the valve, h) has symmetrical and cylindrical expansion of the prosthetic valve resulting in lower rates of leaflet thrombosis and structural valve deterioration, and / or i) prevents allergic response and restenosis associated with nickel content.

The invention belongs to the technical field of microorganisms and biological medicines, and particularly relates to a postbiotic preparation for improving vascular elasticity and relieving hypertension and thrombus as well as a preparation method and application of the postbiotic preparation. Specifically, a strain of lactobacillus rhamnosus is obtained through screening, a postbiotic preparation is successfully developed based on the strain, and tests prove that the lactobacillus rhamnosus has the effects of reducing inflammatory response of vascular endothelium and reducing oxidative stress level so as to promote repair and regeneration of vascular endothelial cells, improve vascular elasticity and quickly improve hypertension; the anti-thrombus effect can be realized. Meanwhile, by optimizing the condition parameters of the preparation process of the metabolite preparation and combining anaerobic fermentation and aerobic fermentation on the lactobacillus rhamnosus, the advantage that metabolites are comprehensive and rich is achieved, and the metabolite preparation has good practical application value.

The present disclosure relates to methods of reducing the risk of thrombosis with thrombocytopenia syndrome (TTS) associated with adenoviral vector therapy.

The invention relates to the technical field of medical instruments, and discloses an intervention pump conveying device which comprises an expansion assembly, a conveying assembly and a pushing assembly, and the conveying assembly comprises a front end assembly and a rear end assembly which are detachably and fixedly connected; the expansion assembly is detachably and fixedly connected with the front end assembly, the front end assembly and the rear end assembly are connected to form an intervention channel allowing the pushing assembly to carry the intervention pump to penetrate through, and the pushing assembly is provided with a pushing channel allowing a pump line of the intervention pump to penetrate through in the axial direction. The pushing assembly can fix or loosen a pump line of the intervention pump so as to achieve pushing and releasing of the intervention pump. The invention further discloses another conveying method of the interventional pump. By constructing a split type collaborative structure, accurate pushing and stable releasing of the interventional pump are achieved, mechanical invasion and occupation to punctured blood vessels are reduced, the risk of complications such as thrombosis and bleeding is reduced, the surgical operation process is simplified, and the minimally invasive property and safety of interventional therapy are improved.

The thrombus aspiration catheter comprises a catheter body and a deformation structure, and the deformation structure comprises a plurality of supporting rings and deformation assemblies arranged between every two adjacent supporting rings; when the axial distance between every two adjacent supporting rings is reduced, the deformation assembly deforms inwards in the radial direction, and the deformation assembly and the two adjacent supporting rings jointly form a variable-diameter channel with the inner diameter firstly decreasing and then increasing from far to near. When the axial distance between every two adjacent supporting rings is increased, the deformation assemblies deform and recover in the radial direction, and the minimum inner diameter of a channel formed by the deformation assemblies and the two adjacent supporting rings is correspondingly increased. The variable-diameter channel can form mechanical wrapping and clamping on the thrombus at the position with the minimum inner diameter, and thrombus escape or far-end embolism in the suction process is effectively prevented; meanwhile, the structure is beneficial for forming a negative pressure enhancing cavity at the far end of the catheter body, and stable grasping and concentrated efficient suction of the thrombus are achieved.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The invention relates to the field of medical auxiliary instruments, in particular to an auxiliary device for preventing lower limb thrombus and foot drop. The problems of lower limb blood circulation disorder, foot drop and heel pressure sores of long-term bedridden patients are solved. The device comprises a foot moving mechanism, a bearing part and a massage part, the foot moving mechanism drives a foot sole to rotate through a motor, and passive bending and stretching of the foot sole are achieved through the magnetic interaction of a movable magnet and a fixed magnet set; the bearing part is provided with a heel accommodating groove and a heel tendon supporting ridge structure, so that the heel pressure is effectively dispersed; the massage part automatically triggers alternate work of a lifting air bag and a massage air bag through movement of the shank through a pneumatic transmission mechanism, and intermittent lifting of the heel and cyclic massage of the shank are achieved. The device can synchronously maintain the motion range of ankle joints, promote blood circulation of lower limbs and relieve heel pressure, and has the advantages of being high in automation degree, high in adaptability, safe and comfortable.

The disclosure provides a subclinical valve leaflet thrombosis auxiliary identification method, system and signal acquisition device after transcatheter aortic valve replacement, belonging to the technical field of heart information acquisition and identification. The subclinical valve leaflet thrombosis auxiliary identification method is used for auxiliary diagnosis of subclinical valve leaflet thrombosis after transcatheter aortic valve replacement, comprising: collecting a heart sound signal, processing the heart sound signal, obtaining preset parameters of the heart sound signal, and the preset parameters at least including time, frequency and energy; determining a systolic period according to the heart sound signal; identifying the highest energy point in the characteristic interval of the systolic period; obtaining the characteristic frequency corresponding to the highest energy point, and judging whether the characteristic frequency is greater than the threshold frequency, if yes, marking the heart sound signal as an abnormal heart sound signal caused by subclinical valve leaflet thrombosis; if not, marking the heart sound signal as a normal heart sound signal. The method solves the problem that the subclinical valve leaflet thrombosis detection mainly uses multi-dimensional computed tomography, which leads to limited scope of application.

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, done or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts ("TEVGs") in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

The present disclosure describes cyclic peptide inhibitors of Factor XI (FXI), preferably FXIa. Also described are pharmaceutical compositions comprising the cyclic peptides and their use in treating conditions, diseases and / or disorders responsive to FXI, preferably FXIa inhibition, including thrombosis or thrombo-inflammatory conditions.

The utility model relates to the technical field of ventricular septum perforation plugging devices, and discloses a novel ventricular septum perforation plugging device which comprises a fixing column and a first disc-shaped net arranged on the outer side of the fixing column, a connecting waist part is further arranged on the outer side of the fixing column, and the connecting waist part is connected with the first disc-shaped net. A second disc-shaped net is arranged on the side, away from the first disc-shaped net, of the connecting waist part, an end is arranged on one side of the second disc-shaped net, and before use, a small screw at the front end of a transmission steel cable is used for being connected with the end, so that the whole compressed plugging device can be transmitted to a heart defect part through a pipeline; the first disc-shaped net and the second disc-shaped net are used for blocking, the defect part can be blocked, the biological membrane can make contact with the heart defect part, the sealing performance is further improved, meanwhile, the polyurethane coating has certain flexibility, friction between the polyurethane coating and the heart defect part is effectively reduced, and the service life of the heart defect part is prolonged. The heparin coating can reduce the risk of thrombus formation, so that the use risk is reduced.

Synthetic hemocompatible vascular grafts manufactured from polyvinyl alcohol-based biomaterials containing crystalline segments of polyvinyl alcohol, which are long-term fully functioning vascular grafts that provide no activity towards immune systems in recognizing surfaces as foreign bodies that would normally lead to fibrosis, platelet activation and subsequent thrombi formation, and thus occlusion of the grafts.

The application discloses an auxiliary exercise device for preventing lower limb thrombus, which comprises a base, an elbow mechanism arranged on the base, a sliding block, a first fixed plate fixed to one end of the base, a second fixed plate fixed to the other end of the base, a first elbow part rotatably arranged on the first fixed plate, a second elbow part arranged on the other end of the first elbow part and connected with the sliding block through a shaft pin, and a supporting pad arranged on the connection between the first elbow part and the second elbow part, and a screw rod arranged on the second fixed plate. The sliding block is driven to slide in the sliding groove on the base through the screw rod, so that the two elbow parts make upward arching and downward flattening movements on the base. When the knee joint of a user is buckled on the supporting pad, the elbow mechanism drives the leg of the user to arch and flatten, so as to facilitate the leg movement of the user and reduce the formation of leg thrombus of the user.

The invention discloses a memory nickel-titanium alloy medical catheter and a manufacturing method thereof, and relates to the technical field of medical instruments, the memory nickel-titanium alloy medical catheter comprises a catheter body, and the catheter body is made of nickel-titanium alloy. The shape memory effect, superelasticity, biocompatibility and other core performance of the nickel-titanium alloy can be guaranteed, and a foundation is laid for clinical application of the catheter; the microscopic cleanliness (the maximum size of non-metallic inclusions is smaller than or equal to 10.0 microns, and the percentage of looseness and the area of the non-metallic inclusions is smaller than or equal to 0.45%) is strictly controlled, so that a fatigue crack starting point can be reduced, the fatigue resistance of the catheter is remarkably improved, and the high-fatigue requirements of high-frequency use scenes such as intracranial stent related catheters are met; the roughness control of the outer surface Ra < = 0.2 [mu] m and the inner surface Ra < = 0.4 [mu] m not only can reduce the adhesion of bacteria and proteins, reduce the risks of inflammation, rejection reaction and thrombosis, improve the biocompatibility, but also can avoid the influence of surface roughness on the subsequent processing quality, and prevent the performance abnormality or fracture of a terminal product.

The invention provides a cobalt-iridium metal complex, nanoparticles, a preparation method and application, and belongs to the technical field of photodynamic therapy drugs. The structural formula of the cobalt-iridium metal complex is shown as a formula (I). The invention also provides a preparation method of the cobalt-iridium metal complex. The invention also provides nanoparticles, the cobalt-iridium metal complex prepared by the invention has a chemiluminescence property, so that the cobalt-iridium metal complex can simultaneously realize photo-thermal, photodynamic and ultrasonic synergistic thrombolysis treatment effects, and the oxidation resistance of the cobalt-iridium metal complex has a remarkable curative effect on a vascular injury part. The complex provided by the invention has good photo-thermal, photodynamic and ultrasonic response capabilities, and can overcome the problems of short excitation wavelength of exciting light and limited light penetration depth required by the existing metal iridium complex. Experiments show that the material has a good treatment effect on thrombus.

The present invention provides a mesenchymal stem cell having blood compatibility, and a preparation method and use thereof, the mesenchymal stem cell inducing exon skipping of an exon 5 by performing gene modification on the exon 5 of an F3 gene, thereby increasing the expression of a selective splicing tissue factor (asTF), and improving the blood compatibility of the mesenchymal stem cell. The present invention relates to a method for inhibiting thrombosis by reducing or inhibiting the expression or activity level of a full-length tissue factor (flTF), which is a blood coagulation promoter, and thereby inhibiting thrombosis.

A TIPS (Transient Invasive Stent) for flow restriction includes a bare stent with a fixed stent connected to one side. A flow-restricting stent is disposed inside the fixed stent. The flow-restricting stent has a conical structure, with the larger end of the conical stent connected to the inner side of the fixed stent, and the smaller end of the conical stent facing the other end of the fixed stent. A drug-eluting layer is disposed inside the fixed stent. In this application, the flow-restricting stent is a streamlined cone shape with a diameter that gradually decreases from one end to the other. This conical design reduces blood flow turbulence and recirculation, lowers the risk of thrombosis, maintains high stent patency, and more rationally balances the relationship between portal hypertension and hepatic encephalopathy, thus improving patients' quality of life. In some patients, it can more stably maintain the postoperative portal vein pressure gradient within the safe range of 10-12 mmHg. The conical structure achieves a smooth pressure gradient change through a gradually decreasing diameter, which is more in line with the principles of fluid dynamics and has high clinical value in preventing hepatic encephalopathy.

The invention relates to the technical field of medical instruments, in particular to an intelligent catheter implanted right heart blood flow management system, a blood pumping impeller comprises a hub structure and a blade assembly fixed around the hub structure, and the near end of a hub is an annular concave curved surface used for guiding blood flow; the blade assembly comprises two symmetrical continuous blades with the same thickness, and the placement angles of the blades are gradually increased from the near end to the far end. The design structure that the segmented hub and the continuous blades are combined is adopted, all segments of the hub structure have different geometrical characteristics, the molded line of each continuous blade is formed by combining an arc and a straight line, and the design of a gradually-increased setting angle and a large wrap angle is matched with the design of a parabola at the far end of the hub, so that the shear stress and the flow dead zone are reduced, and the service life of the impeller is prolonged. Therefore, the risks of hemolysis and thrombus are reduced, the blood flow path is optimized under the miniaturized condition, the catheter implantation type miniature axial flow blood pump is more suitable for the blood flow flowing characteristic in the catheter implantation type miniature axial flow blood pump, and smooth transition from radial inflow to axial outflow of blood can be achieved.

The present disclosure provides methods for using antibodies that bind to Factor XI (FXI) for the purpose of preventing or treating clot formation or thrombogenesis after a surgical procedure. According to certain embodiments, the antibodies are antagonist antibodies that inhibit blood clot formation via the intrinsic pathway without affecting hemostasis, as shown by their effect on prolonging aPTT without affecting PT. As such, these antagonist antibodies may be used to treat or prevent clot formation in a subject requiring such treatment, such as, but not limited to, post-surgery.

The application discloses a multifunctional blood vessel stent with a negative Poisson's ratio structure and a preparation method thereof, relates to the technical field of medical devices, and comprises the construction of a blood vessel stent model with a negative Poisson's ratio structure, selective laser melting additive manufacturing, chemical polishing treatment and surface biomimetic modification treatment. The stent can better adapt to the deformation of a blood vessel by virtue of the negative Poisson's ratio characteristic, reduces incompatibility caused by different deformation steps, the structure of the stent is round and smooth, blood flow turbulence and vortex at sharp corners of a traditional stent can be effectively avoided, the hemodynamic performance is improved, the risk of platelet activation and thrombosis is reduced, a surface gradient coating is prepared, multi-mechanism synergy is realized, and the formation of an endothelial layer on the surface of the stent is facilitated.

This utility model belongs to the field of medical device technology, specifically relating to a double-lumen central venous catheter with anti-wall adhesion and anticoagulation functions, including an extension tube, a double-lumen catheter, and a connector; the extension tube is connected to the double-lumen catheter through the connector; the double-lumen catheter is divided into two inlet lumens by a diaphragm, and the two inlet lumens are connected to two corresponding extension tubes; a side hole and a main hole are provided at the end of the double-lumen catheter, and the end of the double-lumen catheter has a C-shaped segment, with the side hole located on the concave side of the C-shaped segment, and the main hole located at the end of the double-lumen catheter. The C-shaped segment in this design reduces the occurrence of the side hole adhering to the blood vessel wall, reducing the probability of local coagulation and thrombosis when used for pediatric hemodialysis blood drainage; the biomimetic sharkskin microgrooves etched on the outside of the double-lumen catheter reduce resistance to blood flow and thrombus formation; the biomimetic sharkskin microgrooves can be filled with covalently grafted sulfonated heparin-hydrogel, continuously releasing anticoagulant factors, further reducing the formation of wall-attached thrombi.

The present application relates to the technical fields of intravenous indwelling needle, especially to the positive pressure type intravenous indwelling needle assembly, comprising a needle structure, an indwelling hose is connected to one side of the needle structure, characterized in that: a first anti-reflux pre-pressing unit is connected to the liquid inlet end of the indwelling hose, one side of the first anti-reflux pre-pressing unit is connected to an infusion connection unit, the infusion connection unit is connected to the infusion tube of an external infusion device and delivers the liquid medicine into the human body through the indwelling hose, a second anti-reflux spinning unit is installed at the rear end of the needle structure, and a third tube sealing anti-reflux unit is installed on the indwelling hose. The positive pressure type intravenous indwelling needle assembly adopts the anti-reflux mode of positive pressure to effectively prevent the blood from flowing back to the inside of the needle structure and the indwelling hose by using the positive pressure after the infusion tube is pulled out, effectively reduces the thrombosis problem caused by blood reflux, and is safer and more reliable in use.

Occlusion devices are disclosed herein. According to some embodiments, the present technology includes a mesh configured to be positioned within an aneurysm cavity, the mesh having a low-profile configuration for delivery through a catheter to the aneurysm cavity and an expanded configuration for implantation in the aneurysm cavity. The mesh can include a first portion configured to be positioned over the aneurysm neck and a second portion configured to be positioned between the first portion and a dome of the aneurysm. The mesh can include a copper material at the second portion of the mesh, wherein the copper material is configured to promote thrombosis within the aneurysm cavity.

This invention relates to MASP isotypes as inhibitors of complement activation. It also relates to novel ficolin-related peptides and peptides derived from these ficolin-related peptides for the treatment of conditions associated with inflammation, apoptosis, autoimmunity, coagulation, thrombosis, or coagulopathy, and for use as biomarkers. Furthermore, this invention relates to antibodies recognizing the novel ficolin-related peptides and peptides derived therefrom, nucleic acid molecules encoding the peptides, vectors for producing the peptides, and host cells.

The invention relates to an intrusive foldable left ventricle auxiliary device, the near end of a driving shaft is connected with a motor, the far end of the driving shaft is connected with a pump head assembly, and the pump head assembly comprises a foldable impeller driven by the driving shaft and an expandable support covering the periphery of the foldable impeller; the expandable stent is covered with a blood flow flexible film, a blood inlet is formed in the far end of the blood flow flexible film, and at least one blood outlet is formed in the near end area of the blood flow flexible film; the blood flow flexible membrane comprises a first channel, an expansion section and a second channel. When blood passes through the expansion section, the blood flow speed is reduced, the flow distribution is uniform, and the shearing force borne by the blood is directly reduced, so that the hemolysis risk is remarkably reduced from the source; meanwhile, blood flow is more stable, turbulent flow and flow stagnation areas are reduced, and the thrombosis risk is reduced; the near-end edge of the expansion section is located on the far side of the near-end edge of the expandable stent, after blood is decelerated, damage caused by impacting the inner wall of the stent is reduced, and hemolysis is further reduced.

The present application relates to the technical field of animal model construction, and specifically discloses a method for constructing an atherosclerotic plaque thrombosis model. ‑ / ‑ The method comprises the following steps: 1) selecting an ApoE The method provided by the present application is simple in operation, high in repeatability, and can induce atherosclerotic plaque thrombosis under the stimulation of a low-dose LPS, and can obtain a thrombosis rate comparable to that of the prior art, and can be closer to the formation of atherosclerotic thrombosis related to clinical endotoxemia, and better simulate the clinical pathological process.

The invention discloses a zinc alloy stent as well as a preparation method and application thereof. The zinc alloy bracket comprises a zinc-based alloy matrix and a coating arranged on the zinc-based alloy matrix, the coating comprises a zinc layer and a poly-racemic lactic acid coating containing an active drug. According to the zinc alloy stent, the pure zinc layer and the poly-racemic lactic acid coating containing the active medicine are arranged on the zinc-based alloy matrix, so that the early-stage degradation speed of an early-stage zinc alloy implant is slowed down, the number of degradation products is controlled, stimulation of the degradation products to blood vessels is reduced, the probability of occurrence of thrombosis and restenosis in the early-stage and middle-stage is reduced, and the stent has a good application prospect. And the early mechanical property and biocompatibility of the instrument are ensured.

The invention discloses a preparation method of a coronary artery microcirculation disturbance animal model, and belongs to the technical field of biological medicine. According to the method, the stable mouse CMD model can be established by injecting 20-40 [mu] g / mL Calcimycin into the cardiac apex for the first time. Calcimycin is a calcium ion (Ca < 2 + >) carrier commonly used in a laboratory and can transport calcium ions outside cells into the cells, so that the concentration of the calcium ions in the cells is increased. Particularly, when 40 [mu] g / mL of Calcimycin is injected, the pathological severity of the Calcimycin is further aggravated, myocardial fiber arrangement is disordered, boundary is unclear, a large number of myocardial cells are necrotic and dissolved, cavitation is formed, vascular wall degeneration swelling is caused, inflammatory cell infiltration is caused, and thrombus is formed in microvessels.